Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gen-Probe Spin-Off Planned To Avoid Chugai/Roche Diagnostic Overlap

This article was originally published in The Gray Sheet

Executive Summary

Chugai's decision to spin off its wholly-owned diagnostic subsidiary Gen-Probe following a merger with Roche's Japanese unit, Nippon Roche, will preserve worldwide competition between Roche's Cobas AmpliScreen nucleic acid test (NAT) line and Chiron's Procleix NAT, developed with Gen-Probe

You may also be interested in...



Chiron/Gen-Probe Procleix HIV/HCV NAT Test To Cost $10-15 Per Screen

FDA is preparing to release a draft guidance on nucleic acid test (NAT) screening of whole blood samples following approval of Chiron and Gen-Probe's Procleix HIV-1/HCV NAT assay on Feb. 28

Chiron/Gen-Probe Procleix HIV/HCV NAT Test To Cost $10-15 Per Screen

FDA is preparing to release a draft guidance on nucleic acid test (NAT) screening of whole blood samples following approval of Chiron and Gen-Probe's Procleix HIV-1/HCV NAT assay on Feb. 28

DOBI Aims To Be $100 Mil. Firm Within A Year Of ComfortScan Launch

DOBI Medical Systems hopes to gain FDA approval in the third quarter of 2002 for its ComfortScan dynamic breast imaging system based on an ongoing, 10-center, 1,200 patient U.S. pivotal trial of the system for use as an adjunct to mammography

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel